Sensei Biotherapeutics, Inc.

Analysis for Ticker: SNSE

Sensei Biotherapeutics Inc is a clinical-stage business that claims to be developing new immunotherapies for cancer. The company is a shell designed to facilitate a 1.800% inflation of its own stock. The company has 1,3 million regular shares in existence, but is legally moving to dump 24,8 million new shares onto the market. A syndicate of hedge funds, including Baker Brothers and RA Capital, paid an effective price of only 13,85$ per share for this new equity, which is less than half of the 31,79$ price retail investors were paying in late 04/2026. If the existing owners do not vote to allow this massive dilution at the 10/06/2026 annual meeting, the funds have the power to demand all 200$ million of the company cash back by 17/08/2026. This is not an investment in science; it is a meticulously engineered drip feed where private funds extract value from the public before the company burns through its final reserves.